ASH 2022

Acute Lymphoblastic Leukaemia

Blinatumomab candidate for standard-of-care in newly diagnosed B-ALL 

Presented By

Prof. Mark Litzow, Mayo Clinic, MN, USA

Trial

Phase 3, ECOG-ACRIN-E1910 NCTN

Conference

ASH 2022

20 February, 2023 11:07

High-dose methotrexate or standard interim maintenance in young patients with ALL? 

Presented By

Ms Amy Kirkwood, University College London, UK

Trial

UKALL 2011

Conference

ASH 2022

20 February, 2023 11:01

Acute Myeloid Leukaemia

Excellent results for triplet regimen in FLT3-mutated AML 

Presented By

Prof. Nicholas Short, University of Texas, TX, USA

Conference

ASH 2022

20 February, 2023 11:25

MRD by qPCR prognostic of outcomes in venetoclax-treated NPM1-mutated AML 

Presented By

Mr Jad Othman, Guy’s and St Thomas’ NHS Foundation Trust, UK

Conference

ASH 2022

20 February, 2023 11:20

Promising results for triplet therapy with magrolimab in AML

Presented By

Prof. Naval Daver, Anderson Cancer Center, TX, USA

Trial

Phase 3, ENHANCE-3

Conference

ASH 2022

20 February, 2023 11:17

Should we use intensive chemotherapy prior to allo-HCT in relapsed/refractory AML? 

Presented By

Prof. Matthias Stelljes, University of Muenster, Germany

Trial

Phase 3, EATL3-ASAP

Conference

ASH 2022

20 February, 2023 11:13

Chronic Leukaemia

Zanubrutinib wins battle of BTK inhibitors in relapsed or refractory CLL/SLL

Presented By

Prof. Jennifer Brown, Dana Farber Cancer Institute, MA, USA

Trial

Phase 3, ALPINE

Conference

ASH 2022

20 February, 2023 11:40

Ibrutinib plus venetoclax displays long-term benefits in CLL 

Presented By

Prof. John Allan, Weill Cornell Medicine, NY, USA

Trial

Phase 2, CAPTIVATE

Conference

ASH 2022

20 February, 2023 11:28

Multiple Myeloma

Lymphoma

Myeloproliferative Neoplasms

Efgartigimod successful in immune thrombocytopenia 

Presented By

Prof. Catherine Broome, Georgetown University, Washington DC, USA

Trial

Phase 3, ADVANCE

Conference

ASH 2022

20 February, 2023 12:57

INCA033989: novel investigational agent for CALR-mutated MPN

Presented By

Dr Edimara Reis, Incyte Corporation, DE, USA

Conference

ASH 2022

20 February, 2023 12:47

Ruxolitinib mediates clonal evolution of RAS pathway mutations in MPN

Presented By

Dr Nabih Maslah, Université Paris Cité, France

Conference

ASH 2022

20 February, 2023 12:43

Immune Thrombocytopenia

Various Topics

C1 inhibitor deficiency linked to thrombosis

Presented By

Dr Steven Grover, University of North Carolina, NC, USA

Conference

ASH 2022

20 February, 2023 13:18

Durable responses to gene therapy in haemophilia A

Presented By

Prof. Stacy Croteau, Harvard Medical School, MA, USA

Trial

Phase 1/2, SPK-8011

Conference

ASH 2022

20 February, 2023 13:16

Long-term benefits from beti-cel in transfusion-dependent β-thalassaemia

Presented By

Prof. Mark Walters; Prof. Franco Locatelli

Trial

LTF-303

Conference

ASH 2022

20 February, 2023 13:14

Neutrodiet: non-restricted diet is the preferred option after SCT

Presented By

Prof. Federico Stella, Università degli Studi di Milano, Italy

Conference

ASH 2022

20 February, 2023 13:11

Iptacopan offers solution for patients with PNH and residual anaemia after standard-of-care 

Presented By

Prof. Régis de Latour, Saint-Louis Hospital, France

Trial

Phase 3, Apply-PNH

Conference

ASH 2022

20 February, 2023 13:09

Novel therapy may replace standard-of-care prophylaxis for GVHD

Presented By

Prof. Shernan Holtan, University of Minnesota, MN, USA

Trial

Phase 3, BMT CTN 1703

Conference

ASH 2022

20 February, 2023 13:05

LMWH does not result in higher live birth rates in women with inherited thrombophilia 

Presented By

Prof. Saskia Middeldorp, Radboud UMC, the Netherlands

Trial

ALIFE2

Conference

ASH 2022

20 February, 2023 13:01